close Video

NEW You can now listen to Fox News articles!

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer.

Drugmaker Eli Lilly announced on Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to treat adults with specific types of the disease.

Those types include estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer .

WEIGHT LOSS COULD BE JUST A PILL AWAY, STUDY OF NEW MEDICATION SUGGESTS

The once-daily pill is also meant for those who saw disease progression after at least one line of endocrine (hormone) therapy, according to a press release.

In the phase 3 EMBER-3 trial , Inluriyo reportedly reduced the risk of cancer

See Full Page